Category: Press Releases

[Mountain View, September 17, 2025] — Lifespan Research Institute (LRI) today announced the launch of the Public Longevity Group (PLG), a new initiative focused on bridging the cultural gap between scientific breakthroughs in aging and their public acceptance. To kickstart its work, PLG has opened a crowdfunding campaign to develop tools that measure and strengthen...

On September 18, 2025, Longevity Xplorer (LongX) will be hosting the first-ever "Youth in Longevity Biotech Showcase", a virtual event featuring lightning talks from young professionals in longevity fellowships around the world. The event will cover fellow contributions and highlight the importance in supporting the next generation of leaders in aging biology. LongX welcomes the...

Longevity Investors, launched back in 2020 as the first industry event series fully focusing on investors, wants to educate investors and connect them to the leading key opinion leaders in the industry. The vision and ambition of Longevity Investors is to bring more capital into the longevity market. Beyond its flagship gatherings, Longevity Investors sustains...

Longevity medicine is rapidly emerging as a credible, fast-growing discipline in modern healthcare, powered by rigorous science and significant global investment. On October 4–5, 2025, the Asia-Pacific Longevity Society will host the inaugural Asian Pacific Longevity Medicine International Summit (APAC-LMIS) at the SkyCity Marriott Hotel in Hong Kong, in partnership with several leading international longevity...

Abu Dhabi is set to host the Middle East’s first-of-its-kind conference and exhibition dedicated to longevity science, biotechnology, regenerative medicine, ultra-personalised wellness, and AI-powered healthcare innovation, Revive ME. Taking place on 26 - 27 November 2025 at Beach Rotana, Abu Dhabi, this transformative event will bring together global pioneers, scientific leaders, and healthcare futurists, positioning...

BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the first participant has been dosed in a Phase 1 clinical trial evaluating BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency...